Tuesday, December 27, 2011

Kudos to Louisiana Senator David Vitter


I Can Get Into This [Kathryn Jean Lopez]
(Washington, D.C.) – U.S. Sen. David Vitter today introduced the Ethical Stem Cell Research Tax Credit Act of 2008, which would provide a federal tax credit to entities who conduct stem cell research that does not involve the destruction of – or risk of injury to – human embryos. The bill provides for a tax credit equal to 30 percent of the qualified stem cell research expenses.
“We are only beginning to understand the full potential of adult stem cell research,” said Vitter.

“This research is a source of great hope for so many people who suffer from terrible, degenerative diseases. But we must be responsible in our approach. We should not destroy human embryos when a better, ethical alternative exists in the form of adult stem cells.”
Experimentation on stem cells harvested from human embryos results in the destruction of these embryos during the extraction process. Vitter’s bill seeks to promote the expansion of research programs that utilize adult stem cells as an effective and ethical source for research purposes.

“All human life is precious, whether it is in the beginning stages or the end. Adult stem cell research represents a non-destructive means of preserving human life, and this bill can help further this approach. This sort of medical research can result in significant leaps forward in disease prevention, management and cures while preserving human life in all its stages,” Vitter said.

This is an older article but shows the support by our government officials see in the benefits that adult stem cell therapies, treatments, and research. The industry has come a long way in the last 4 years but has a long way to go to catch up with some of the other countries around the globe.........MrCordBlood

Monday, December 19, 2011

Tripp Roth's tears reveal pain epidermis bullosa strikes


I strongly urge you to see the story of one of the bravest young boys I will ever know. Tripp Roth has courage that is unparalleled and his mother Courtney should be looked upon as an angel, the epitome of all that is good in this world. Her unconditional love and total unselfishness for her own life to care for her son is one of if not the most heartwarming stories I have ever heard.

Epidermolysis-Bullosa is an excruciatingly painful disease. Research is being conducted as we speak using adult and cord blood stem cells but SO MUCH MORE needs to be done. I ask that all that read this to do me one request; share this story to someone and ask them to do the same so we can create awareness about the daily battles children like Tripp go through on a daily basis. TOGETHER we can make a difference. Do not do this for me or yourself, do it for Tripp...........MrCordBlood

Thursday, December 15, 2011

With stem cells, ailing dog may learn some new tricks


Stem cells could help an old dog learn new tricks.

A veterinarian in the Grand Rapids area performed stem cell therapy Tuesday on a dog named Boris, a $1,500 treatment that could relieve discomfort in the 11-year-old's arthritichips and legs.

"It's a lot of money, no doubt about it," owner Paul Bultinck told The Grand Rapids Press (http://bit.ly/uaauSs ). "But the dogs become one of your family. If you can swing it, you do. A loved one in your family certainly takes a very high priority."

James Kelley says it's the first time he's performed it on a dog at his Walker clinic after investing more than $10,000 in equipment and materials to process the stem cells.

Kelley used an enzyme to remove stem cells from a portion of Boris's fat. The cells were mixed with plasma from a blood sample and injected into hip and knee joints. Advocates say the cells help the animal's body heal.

"The studies go out three years now, and the animals, after three years, are OK," said Kelley, who believes Boris could start feeling better in two months.

The dog, an 80-pound Chow mix, doesn't run and jump like he did in his younger years. He already is given anti-inflammatory medication and undergoes soft-tissue laser therapy every three weeks. If the stem-cell procedure works, those treatments may become unnecessary. More stem cells can be frozen for future use.

"I'm very optimistic about it," Bultinck said. "I hope this will help his hip."

Boris isn't the only dog in the family getting special attention. His sister, Natasha, is scheduled to undergo the same treatment next week. She has had arthritis even longer and had hip surgery about five years ago.


Information from: The Grand Rapids Press, http://www.mlive.com/grand-rapids

I am a dog lover and there are millions more out there in the world. Family pets become just that, "FAMILY." Stem cells can help us all. Great story..........MrCordBlood

Wednesday, December 14, 2011

StemCyte adds world class talent to its North America and Global Operations


COVINA, Calif., Dec. 13, 2011 /PRNewswire via COMTEX/ -- Renowned experts in cord blood collection, processing and transplantation have joined StemCyte, Inc. The added resources are evidence of its commitment as a worldwide industry leader in developing and providing the safest and most effective cord blood therapies for treating patients.

Dr. Wise Young MD PhD has agreed to join StemCyte as its Global Medical Director. He will serve in a voluntary (unpaid) and part-time capacity to help StemCyte organize its medical and research programs based on his firm belief in StemCyte as the best company today delivering cord blood stem cell units for life-saving therapies. Professor Young is the founding Director of the W. M. Keck Center for Collaborative Neuroscience and helped found the New Jersey Stem Cell Research Center at Rutgers, the State University of New Jersey. He has been voluntarily advising StemCyte since 2003 on its research and development programs. He is currently conducting clinical trials to assess the safety and efficacy of human UCB cells and lithium treatment of chronic and acute spinal cord injury using StemCyte cord blood units. Prof. Young will help StemCyte develop stem cell therapies for new conditions such as spinal cord injury, stroke, and genetic disorders. He will work with the team at StemCyte to develop the highest quality standards at its facilities and to organize collaborations with scientists worldwide to develop cutting-edge therapies with UCB and other stem cells.

"Wise is a unique and incredibly talented individual that I have been privileged to know and work with for the past 16 years," said Chairman and CEO, Ken Giacin. "StemCyte is fortunate to have the benefit of his scientific expertise, dedication to our mission and passion for developing new promising therapies using high quality cells from cord blood."

In addition, StemCyte Inc. has recruited the following individuals to join its team:

Dr David Senitzer, PhD, a leading laboratory and technology expert, will be StemCyte's new Laboratory Director responsible for all UCB and HLA laboratory operations. Senitzer has been the Clinical Professor of Hematology and Hematopoietic Stem Cell Transplantation and Director of the Histocompatibility Laboratory at The City of Hope National Cancer Center since 1994. He will oversee StemCyte's unique dual processing capabilities ensuring that its laboratory operations comply with all current and anticipated regulatory protocols.

Dr. Jennifer Willert, MD will join StemCyte as a Medical Officer. Dr. Willert is an Associate Clinical Professor, University of California-San Diego School of Medicine. She specializes in blood and marrow transplant with the Division of hematology/oncology/BMT. She has prescribed and used cord blood units for treatment of critically ill children and supports broader accessibility of these life-saving resources to patients in need. Dr. Willert has a strong interest in stem cell research and regenerative medicine, along with emerging clinical applications using UCB.

Dr. Karen Taylor, MD, a Board Certified Obstetrician has joined StemCyte to oversee its collection methods, as well as its education programming for expecting parents, doctors and other health professionals engaged in the collection, documentation and chain of custody of UCB units.

"We are pleased to be adding Doctors Jen Willert, Karen Taylor and David Senitzer to oversee our transplant, collection and lab-processing activities," said Giacin. "These outstanding people will enhance StemCyte's unique hybrid business model in the cord blood industry. We could not be happier to have such passionate, committed and expert personnel added to our team. Their caliber demonstrates our deep and continued commitment to providing life-saving UCB products globally to patients in need."

To continue improving the accessibility of cord blood banking, StemCyte not only processes both privately banked and publicly donated units to the same high standard, but is focused on improved collection education and methods. StemCyte's labs in California and Taiwan have been approved under the National Marrow Donor Program's (NMDP) FDA Investigational New Drug (IND) Application. StemCyte is actively preparing for its US FDA Biologics License Application (BLA).

About StemCyte, Inc.

Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1,500 cord blood products for over 70 life-threatening diseases to over 200 leading worldwide transplant centers. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies. The Company supports the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and the developments of trials investigating regenerative spinal cord therapies. StemCyte is one of the only for-profit companies contracted by the US Department of HHS to help contribute clinical grade cord blood units to the public National Cord Blood Inventory for unrelated transplants. Its operational headquarters are located in Covina, Ca. To learn more visit www.StemCyte.com .

SOURCE StemCyte, Inc.

Copyright (C) 2011 PR Newswire. All rights reserved

Great job StemCyte!!!!............MrCordBlood

Tuesday, December 13, 2011

Researchers Discover Safe Way To Repair Sickle Cell Disease Genes


"Researchers have developed a way to use patients’ own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin."

Sickle Cell Anemia is a painful disease that is one of the most common forms of anemia affecting our population, especially minority children. It is VERY PROMISING news that researchers may be able to use one's own stem cells to cure the thousands that suffer daily. Great news and kudos to all the hardworking researchers out there putting in countless hours daily in an attempt to make the world a better place for todays and tomorrows generations.

Monday, December 12, 2011

Stem-cell treatment helps American see again, view Taj Mahal


"Seven years after he lost his sight following acute illness, it was no less than a miracle for 62-year-old Carl Stevens when he was able to catch a glimpse of the Taj Mahal after treatment by an Indian doctor.

An American citizen, Stevens, lost his vision in 2004. He is now recovering his sight in what can be called nothing short of a medical miracle, made possible through stem-cell therapy."

WOW, what an amazing story!

Thursday, December 8, 2011

Sem Cell Therapy Poised to Transform Medicine As Dozens of Clinical Trials Show Success


Dozens of adult stem cell treatments are moving through clinical trials and showing early success, raising hopes that some could reach the market within five years.

'It will only take a few successes to really change the field,' said Gil Van Bokkelen, chief executive of Athersys and chairman of the Alliance for Regenerative Medicine.

'As you see things getting closer and closer to that tipping point, you're going to see a frenzy of activity take place.'

Many of the trials focus on heart disease and inflammatory conditions, some of the biggest markets in medicine. The cells used are derived from adult tissue such as fat, or bone marrow, thereby circumventing the ethical concerns raised by the use of cells derived from embryos.

With Geron's recent exit from the embryonic stem cell industry all together and the continued success and progress using adult stem cells from sources such as cord blood, adipose tissues, and the placenta just to name a few, a "revolution in medicine" is not at all far-fetched. It is becoming clear that the use of adult stem cells and their abilities to regenerate into many different types of tissues, blood, and other cells will be the stamped with the "physician treatment of choice" in the not so distant future. Some of the most promising studies are in diseases that are some of the most common afflicting men and women today. This is just always my opinion but I am going to pull out my crystal ball and give you a look into the future of what I think we will see. Here is a list of potential future applications that are in clinical trials or not far from it and may be coming to a treatment center near you sooner than later. The list below are potential future applications using umbilical cord blood stem cells.

1. Alzheimer’s Disease
2. Cerebral Palsy
3. Cardiac Disease
4. Diabetes
5. Epidermolysis Bullosa (rare genetic skin disease)
6. Lupus

7. Multiple Sclerosis
8. Muscular Dystrophy
9. Parkinson’s Disease
10. Rheumatoid Arthritis
11. Spinal Cord Injury
12. Stroke

Thursday, December 1, 2011

Christian Pope, M.D.: Cord Blood Banking Worth Considering


"Expecting a baby is an exciting and overwhelming experience for both new and veteran parents, who are faced with many important decisions to make for the family's future.

So, parents, you've got the car seat, the Mercedes-Benz of strollers, and the deluxe diaper bag... but have you considered perhaps the most important preparation of all?

Cord blood banking is the collection and storage of the stem cells found in your newborn's umbilical cord, and should be considered by any parent-to-be. It is a rich, non-controversial source of stem cells that can only be collected at the time of birth."

Great perspective from a M.D. on why cord blood banking is a wise decision to make for the future well-being of your child. The number of transplants using cord blood stem cells were 1% in 2000 and now account for 22% of transplants. Do your research and I urge all parents to become educated and aware of the benefits cord blood banking offers> It could one day looking back be the best decision you've ever made!!!

Cord Blood Chronicles: Adult Stem Cell Therapies are the Future, Scientis...

Cord Blood Chronicles: Adult Stem Cell Therapies are the Future, Scientis...: http://www.ncregister.com/daily-news/adult-stem-cell-therapies-are-the-future-scientist-says1/ How important is adult stem-cell technology...